Navigation Links
Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
Date:1/4/2011

CHICAGO, Jan. 4, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it will present at the Biotech Showcase 3rd Annual Healthcare Conference held January 10-12th in San Francisco.

(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

Advanced Life Sciences' President and Chief Financial Officer, John Flavin, will make a corporate presentation to prospective corporate partners and investors at the Biotech Showcase 2011 Conference on Wednesday, January 12 at 9:00 AM PST. The Company's presentation will be delivered in the Stockton Room at the Parc 55 Wyndham-Union Square, 55 Cyril Magnin Street in Union Square San Francisco.

The Company is also scheduled to participate in the Biotech Showcase's one-on-one partnering sessions throughout the three day conference.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers.  These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
2. Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers
3. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
4. Wiley-VCH launches new journal Advanced Energy Materials
5. Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
6. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
7. StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
8. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
9. ERC advanced grant for Professor Zandbergens nanolaboratory
10. IRS Awards Cash Grant to Advanced Life Sciences Under the Qualifying Therapeutic Discovery Project
11. Advanced Life Sciences Announces US Army Collaboration to Research and Develop Restanza for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):